Business Context and Reporting Period
Company: Intuitive Surgical, Inc. (ISRG)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Intuitive Surgical develops, manufactures, and markets the da Vinci surgical systems and the Ion endoluminal system. The company operates as a single reportable segment, providing a comprehensive ecosystem of robotic-assisted surgical systems, instruments, accessories, learning, and services to advance minimally invasive care. As of December 31, 2024, the company had an installed base of 9,902 da Vinci surgical systems and 805 Ion systems globally.
Key Financial Metrics
| Metric (in millions) | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenue | $8,352.1 | $7,124.1 | +17% |
| Gross Profit | $5,634.2 | $4,729.5 | +19% |
| Gross Margin | 67.5% | 66.4% | +110 bps |
| Operating Income | $2,348.9 | $1,766.8 | +33% |
| Net Income (Attributable to ISRG) | $2,322.6 | $1,798.0 | +29% |
| Diluted EPS | $6.42 | $5.03 | +28% |
| Cash, Cash Equivalents, and Investments | $8,832.4 | $7,343.2 | +20% |
| Operating Cash Flow | $2,415.0 | $1,813.8 | +33% |
Revenue Composition (2024):
- Instruments and Accessories: $5,079.0 million (61% of total revenue)
- Systems: $1,966.0 million (24% of total revenue)
- Services: $1,307.1 million (16% of total revenue)
- Recurring Revenue (Instruments, Accessories, Services, Operating Leases): $7,040.3 million (84% of total revenue)
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 17% driven by a 19% increase in instruments and accessories revenue and a 17% increase in systems revenue. Procedure volume for da Vinci systems grew 17% to approximately 2.68 million, while Ion procedures grew 78% to approximately 95,500.
- System Placements: Total da Vinci system placements increased 11% to 1,526 units (up from 1,370 in 2023), including 362 placements of the new da Vinci 5 system. Ion system placements increased 27% to 271 units.
- Profitability: Operating income grew 33% to $2.35 billion, outpacing revenue growth due to operating leverage and improved gross margins. Gross margin expanded to 67.5% from 66.4%, aided by fixed cost leverage and lower logistics costs, partially offset by launch costs for the da Vinci 5 system.
- Geographic Mix: U.S. revenue accounted for 67% of total revenue, while Outside the U.S. (OUS) revenue accounted for 33%. OUS procedure growth was 23%, driven by general surgery, urology, and gynecology.
- Leasing Activity: Operating lease revenue increased to $654 million (from $501 million), with variable usage-based lease revenue rising to $338 million. The proportion of da Vinci systems placed under operating leases increased to 51% of total placements.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Management Commentary:
- da Vinci 5 Launch: The company is in the early stages of launching the da Vinci 5 system, with 362 units placed in 2024. Management expects a phased launch over several quarters to mature supply and manufacturing processes.
- China Market: System demand in China was impacted by increasing competition from domestic companies and a government campaign targeting the healthcare sector, resulting in fewer placements than anticipated. The impact remains uncertain.
- Capital Expenditures: Capital expenditures are expected to range between $650 million and $800 million in 2025, primarily for facilities-related investments to scale manufacturing.
- Tariff Risks: The company highlighted potential material impacts on gross profit in 2025 if proposed 25% tariffs on imports from Mexico (where a significant majority of instruments and accessories are manufactured) are implemented.
Key Risks and Contingencies:
- Regulatory Environment: Ongoing regulatory scrutiny in China regarding pricing and quotas; potential delays in FDA or foreign regulatory approvals for new products or indications.
- Competition: Increasing competition in the robotic-assisted surgery market, particularly in China, and from companies developing alternative therapeutic approaches (e.g., weight loss drugs impacting bariatric surgery volumes).
- Supply Chain: Reliance on sole- and single-sourced suppliers; potential disruptions from geopolitical conflicts or trade barriers.
- Legal Proceedings: The company is involved in various product liability, patent, and antitrust litigation. A trial regarding antitrust claims by Surgical Instrument Service Company (SIS) commenced in January 2025, with the court finding in Intuitive's favor on all antitrust claims as of January 28, 2025. Other antitrust class actions remain pending with no trial dates set.
Important Facts for Investor Verification
- Tariff Exposure: Verify the status of proposed U.S. tariffs on Mexican imports and their potential impact on 2025 gross margins, given that a significant majority of instruments are manufactured in Mexicali, Mexico.
- China Market Dynamics: Monitor the resolution of the Chinese government's healthcare sector campaign and the competitive landscape, as these factors directly influenced 2024 system placements and may impact future growth in the region.
- da Vinci 5 Adoption: Track the commercial rollout and utilization rates of the da Vinci 5 system to assess its contribution to future revenue and margin expansion.
- Leasing Mix: Observe the continued shift toward operating lease arrangements (now 51% of da Vinci placements) and the associated volatility in revenue recognition and credit risk exposure.
- Legal Outcomes: Follow the status of pending antitrust class actions (e.g., In Re: da Vinci Surgical Robot Antitrust Litigation) and product liability cases, as outcomes could result in significant costs or reputational damage.